New Results
Upregulation of Somatostatin Receptor Type 2 in a Receptor-Deficient In Vivo Pancreatic Neuroendocrine Tumor Model Improves Tumor Response to Targeted 177Lu-DOTATATE
Rupali Sharma, Bhargav Earla, Kwamena Baidoo, Martha A. Zeiger, James P. Madigan, View ORCID ProfileFreddy E. Escorcia, Samira M. Sadowski
doi: https://doi.org/10.1101/2022.04.25.489401
Rupali Sharma
1Endocrine Surgery Section, Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Bldg 10, Bethesda, MD, USA
Bhargav Earla
1Endocrine Surgery Section, Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Bldg 10, Bethesda, MD, USA
2UAB Heersink School of Medicine, 1670 University Blvd, Birmingham, AL, USA
Kwamena Baidoo
3Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Bldg 10, Bethesda, MD, USA
Martha A. Zeiger
4Office of Surgeon Scientists Programs, Center for Cancer Research, National Cancer Institute, NIH, Bldg 31, Bethesda, MD, USA
James P. Madigan
1Endocrine Surgery Section, Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Bldg 10, Bethesda, MD, USA
Freddy E. Escorcia
3Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Bldg 10, Bethesda, MD, USA
Samira M. Sadowski
1Endocrine Surgery Section, Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, Bldg 10, Bethesda, MD, USA

Article usage
Posted April 26, 2022.
Upregulation of Somatostatin Receptor Type 2 in a Receptor-Deficient In Vivo Pancreatic Neuroendocrine Tumor Model Improves Tumor Response to Targeted 177Lu-DOTATATE
Rupali Sharma, Bhargav Earla, Kwamena Baidoo, Martha A. Zeiger, James P. Madigan, Freddy E. Escorcia, Samira M. Sadowski
bioRxiv 2022.04.25.489401; doi: https://doi.org/10.1101/2022.04.25.489401
Upregulation of Somatostatin Receptor Type 2 in a Receptor-Deficient In Vivo Pancreatic Neuroendocrine Tumor Model Improves Tumor Response to Targeted 177Lu-DOTATATE
Rupali Sharma, Bhargav Earla, Kwamena Baidoo, Martha A. Zeiger, James P. Madigan, Freddy E. Escorcia, Samira M. Sadowski
bioRxiv 2022.04.25.489401; doi: https://doi.org/10.1101/2022.04.25.489401
Subject Area
Subject Areas
- Biochemistry (13924)
- Bioengineering (10604)
- Bioinformatics (33730)
- Biophysics (17365)
- Cancer Biology (14451)
- Cell Biology (20441)
- Clinical Trials (138)
- Developmental Biology (11014)
- Ecology (16257)
- Epidemiology (2067)
- Evolutionary Biology (20569)
- Genetics (13538)
- Genomics (18851)
- Immunology (13985)
- Microbiology (32634)
- Molecular Biology (13585)
- Neuroscience (71128)
- Paleontology (533)
- Pathology (2228)
- Pharmacology and Toxicology (3788)
- Physiology (5979)
- Plant Biology (12185)
- Synthetic Biology (3410)
- Systems Biology (8265)
- Zoology (1879)